AVEO Oncology

AVEO Oncology is a US-based biopharmaceutical company specializing in the development and commercialization of innovative therapies for cancer treatment. Their focus is on improving patient outcomes through targeted therapies. Founded in 2001 and headquartered in Boston, US, AVEO Oncology is dedicated to developing therapies for oncology. The company was previously involved in public and private funding rounds, transitioning from a public to a private model.

The latest funding round, LP Direct, raised USD 571. 00 mn, bringing the total amount raised to USD 571. 00 mn. Michael Bailey serves as the CEO.

AVEO Oncology is focused on developing and commercializing innovative oncology therapies, including its core product, FOTIVDA (tivozanib), which is FDA-approved for advanced renal cell carcinoma (RCC). FOTIVDA selectively inhibits vascular endothelial growth factor receptors, aiding in tumor growth inhibition. Additionally, AVEO is advancing other candidates like Ficlatuzumab and AV-380, targeting various cancer progression pathways, primarily for oncologists and healthcare providers in North America and Europe. In 2021, AVEO Oncology generated revenue of USD 42.

30 mn, while the EBITDA for the same year was USD -49. 41 mn. The company's revenue is derived mainly from the commercialization of FOTIVDA through direct sales to hospitals and oncology clinics, supported by partnerships with pharmaceutical distributors. AVEO Oncology plans to leverage recent funding to advance its pipeline and expand its market presence.

The company is focused on launching new products aimed at enhancing treatment options for oncology, though specific release dates are not mentioned. Furthermore, AVEO aims to expand its reach into additional geographic markets, although the exact regions targeted for expansion are not specified.